2-chloro-4-methyl-thiophene | 91505-25-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 2-chloro-4-methyl-thiophene
• 英文别名: 2-Chlor-4-methyl-thiophen；5-Chloro-3-methylthiophene；2-Chloro-4-methylthiophene
• CAS: 91505-25-8
• 化学式: C₅H₅ClS
• 分子量: 132.614
• InChiKey: QUYLXJZXWFABNS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-chloro-4-methyl-thiophene 生成 1-(5-Chloro-3-methylthiophen-2-yl)ethanone
  参考文献：
  名称：

  BINDER, D.;NOE, C.

  摘要：

  DOI：
• 作为产物：
  描述：

  2-bromo-5-chloro-3-methylthiophene 在 溶剂黄146 作用下， 以 水 为溶剂， 以133 g (59%)的产率得到2-chloro-4-methyl-thiophene
  参考文献：
  名称：

  Derivatives of thiophene-2-carboxylic acid and their pharmaceutically

  摘要：

  该披露涉及噻吩-2-羧酸的新衍生物及其药用可接受的酸或碱盐，以及其制备方法。该发明的化合物具有下列结构式：##STR1##其中噻吩核的第3或第4位的R为氢、甲基、氯或溴，R.sub.1为氢或C.sub.1-C.sub.4-烷基。这些化合物对血栓素合酶有明显的强抑制作用，可用于治疗炎症、高血压、血栓、中风、哮喘、心绞痛、缺血性心脏病、缺血性疾病、偏头痛以及与糖尿病相关的血管并发症。

  公开号：

  US04590203A1

文献信息

• Imidazole Compound
  申请人：Kusama Mari

  公开号：US20080009506A1

  公开（公告）日：2008-01-10

  An imidazole compound of the formula: wherein Ring A is benzene or a heterocyclic ring; G is alkylthio, alkylsulfonyl, optionally substituted phenyl, or optionally substituted heterocyclic ring group, etc.; Ring C is imidazole; R 1 is carbamoyl, etc.; R 2 is cyano, nitro, hydroxyl, an alkoxy, a halogen, carboxy, an alkoxycarbonyl, carbamoyl, amino, an alkyl, etc.; m is 0 to 2; and R 4 is hydrogen, an alkyl, etc., or a pharmaceutically acceptable salt thereof, is a large conductance calcium-activated K channel opener useful for treatment of pollakiuria, urinary incontinence, etc.

  一种咪唑化合物的化学式： 其中环A是苯或杂环；G是烷硫基、烷磺酰基、可选择取代的苯基或可选择取代的杂环基团等；环C是咪唑； R1是氨基甲酰基等； R2是氰基、硝基、羟基、烷氧基、卤素、羧基、烷氧羰基、氨基、烷基等；m为0至2；以及 R4是氢、烷基等，或其药用可接受盐，是一种用于治疗尿频、尿失禁等的大电导钙激活K通道开放剂。
• [EN] PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP<br/>[FR] DERIVES DE PYRROLOPYRIMIDINE ET DE PYRROLOPYRIDINE A SUBSTITUTION PAR UN GROUPE AMINO CYCLIQUE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2004058767A1

  公开（公告）日：2004-07-15

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.[SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I]:has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  本发明的一个目的是提供一种针对CRF受体的拮抗剂，该拮抗剂可作为治疗或预防剂用于CRF被认为参与的疾病，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮肤炎、精神分裂症等疾病。[解决方案] 一种用下式[I]表示的含有环状氨基团的吡咯吡嘧啶或吡咯吡啶衍生物具有高亲和力对CRF受体，并对CRF被认为参与的疾病有效。
• [EN] PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRROLOPYRIMIDINE ET DE PYRROLOPYRIDINE SUBSTITUÉS PAR UN GROUPE AMINO CYCLIQUE SERVANT D'ANTAGONISTES DU CRF
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2006001511A1

  公开（公告）日：2006-01-05

  [PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against CRF receptors and/or an agonist for receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. [SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by the following formula [I] has a high affinity for CRF receptors and/or δ receptors, and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种针对CRF受体的拮抗剂和/或对受体的激动剂，作为治疗或预防与CRF有关的疾病的有效药物，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物依赖、脑梗死、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、癫痫、皮肤炎、精神分裂症、疼痛等疾病。具有以下式[I]所示的带有环状氨基团的吡咯吡嘧啶或吡咯吡啶衍生物对CRF受体和/或δ受体具有高亲和力，并对与CRF有关的疾病有效。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014135483A1

  公开（公告）日：2014-09-12

  The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

  本发明公开了式I化合物，其中式I中的变量如本文所述。还公开了含有这些化合物的药物组合物，以及使用式I化合物预防或治疗HCV感染的方法。
• [EN] ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS FOR USE<br/>[FR] BLOQUEURS DE CANAUX IONIQUES SUBSTITUÉS PAR UN ESTER ET MÉTHODES D'UTILISATION
  申请人：NOCION THERAPEUTICS INC

  公开号：WO2020185915A1

  公开（公告）日：2020-09-17

  The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

  本发明提供了式（I）的化合物，或其药学上可接受的盐。该发明的化合物、组合物、方法和试剂盒对于治疗疼痛、瘙痒和神经源性炎症是有用的。